Amundi
COGT icon

Amundi’s Cogent Biosciences COGT Stock Holding History

Amundi’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Buy
+5,515
New +$204K ﹤0.01% 1862
2025
Q2 		– Sell
-123
Closed -$656 – 1770
2025
Q1 		$656 Buy
123
+11
+10% +$86 ﹤0.01% 2102
2024
Q4 		$908 Buy
+112
New +$1.12K ﹤0.01% 2032

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Amundi's COGT Position: Q1 2026 in Review

Amundi opened a new position in Cogent Biosciences (COGT) in Q1 2026: 5,515 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #1862 among its holdings. This is a return to the name: Amundi previously reported a position in COGT as recently as Q1 2025.

Amundi first reported a position in COGT in Q4 2024 and has held it in 3 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Amundi held 5,515 shares of Cogent Biosciences worth $212K as of Q1 2026.
  • Cogent Biosciences was a new Amundi position in Q1 2026.
  • Cogent Biosciences made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1862 holding.
  • Amundi first reported a position in Cogent Biosciences in Q4 2024 and has held it in 3 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.